Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration.
Level 5 - mechanism / opinion, no new human data
Narrative review and expert commentary without systematic search methodology
PubMed 26304874 · doi:10.1200/JCO.2014.59.1636
What was done
The authors reviewed English-language literature on advances in the biology and treatment of childhood and adolescent acute lymphoblastic leukemia, focusing on collaborative group studies. Major acute lymphoblastic leukemia study group committee chairs reviewed and revised the resulting article.
What was found
The review notes that long-term survival rates for pediatric acute lymphoblastic leukemia approach 90%. Collaborative research and genome-wide analyses improved treatment strategies for specific subtypes (including infant, MLL-rearranged, Philadelphia chromosome-positive, and Philadelphia chromosome-like disease), identified recurrent genetic abnormalities responsive to tyrosine kinase inhibitors, characterized determinants of drug resistance and toxicity, and identified susceptibility polymorphisms explaining racial and ethnic differences in incidence. No numerical comparative statistics or effect sizes were reported in the abstract.
Why it matters
International collaboration across study consortia has enabled systematic genomic discovery and targeted therapy integration to optimize survival and personalized treatment in pediatric leukemia.
Limits
This is a narrative review rather than a formal systematic review. The abstract provides generalized historical and clinical achievements without specified search parameters, study selection criteria, sample sizes, or quantitative meta-analytic data.
Cited by
- supports Certain childhood leukemias that were previously fatal now have cure rates between 90% and close to 100%.